CD38 and Miyoshi myopathy: The therapeutic landscape of MM has evolved considerably in the last several years, with most patients now being treated with various triplet combinations of IMiDs, PIs and, most recently, anti-CD38 mAbs in the first line or initial relapses based on many studies that consistently indicate the impressive efficacy of these regimens15–17.